Bal Pharma Limited share price
NSE: BALPHARMA · ISIN INE083D01012
Key numbers
- Market cap
- ₹ 171 Cr
- Current price
- ₹ 107.71
- 52-week high / low
- ₹ 125 / 60
- Stock P/E
- 23.8
- Book value
- ₹ 51.7
- Dividend yield
- 1.11%
- ROCE
- 8.7%
- ROE
- 7.9%
- Debt to equity
- 2.03
- Sales growth (3 yrs)
- 0.1%
- Profit growth (3 yrs)
- 34.7%
- 1-year return
- 27.7%
About Bal Pharma Limited
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 66 | 74 | 88 | 84 | 89 |
| Operating profit | 6 | 6 | 10 | 11 | 8 |
| Net profit | 0 | 1 | 2 | 4 | 1 |
| EPS (₹) | 0.13 | 0.45 | 1.12 | 2.26 | 0.71 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.